SamirVasantParikhMDFASN
Nephrology • Columbus, OHGlomerular Disease, Hereditary Kidney Disease Genetics
Professor of Clinical Medicine, Nephrology at The Ohio State University
Dr. Parikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
543 Taylor Ave
Columbus, OH 43203Phone+1 614-293-4837Fax+1 614-293-3125
Summary
- Dr. Samir Parikh is a nephrologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 11 years. He specializes in the glomerular diseases with a special focus in the management of lupus nephritis, thrombotic microangiopathy and monoclonal gammopathy. He is experienced in hypertension, general nephrology, acute renal failure, and chronic kidney disease management.
Education & Training
Ohio State University HospitalFellowship, Nephrology, 2009 - 2011- Ohio State University HospitalResidency, Internal Medicine, 2006 - 2009
University of Cincinnati College of MedicineClass of 2006
Certifications & Licensure
OH State Medical License 2006 - 2026- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
- ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Start of enrollment: 2013 Jul 01
- Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Start of enrollment: 2013 Nov 20
- Join now to see all
Publications & Presentations
PubMed
- 157 citationsA randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active l...Brad H. Rovin, Neil Solomons, William F. Pendergraft, Mary Anne Dooley, James A. Tumlin
Kidney International. 2019-01-01 - 195 citationsEfficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Brad H. Rovin, Y K Onno Teng, Ellen M. Ginzler, Cristina Arriens, Dawn J. Caster
Lancet. 2021-05-29 - 225 citationsUpdate on Lupus Nephritis: Core Curriculum 2020.Samir V. Parikh, Salem Almaani, Sergey V. Brodsky, Brad H. Rovin
American Journal of Kidney Diseases. 2020-03-24
Lectures
- Renal Biopsy: Clinical Correlations 2019American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/9/2019
Other
- Differential diagnosis and evaluation of glomerular diseaseParikh SV, Hebert LA
http://www.uptodate.com/contents/differential-diagnosis-and-evaluation-of-glomerular-disease
UpToDate, Wolters Kluwer Health - 2012-06-13
Press Mentions
Lupus Nephritis Drug Voclosporin Shows Efficacy, Safety over 3 YearsNovember 29th, 2022- Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisNovember 15th, 2021
- Kezar Reports Third Quarter Financial Results and Provides Business UpdateNovember 9th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Gujarati
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
